Inhibrx Biosciences (INBX) Receivables (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly Receivables of -$706000.0 for Q4 2025, down 1338.6% year-over-year from $57000.0 in Q4 2024, and down 197.11% quarter-over-quarter from $727000.0 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Receivables (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Receivables for 3 consecutive years, with -$706000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables fell 1338.6% year-over-year to -$706000.0; the TTM figure through Dec 2025 stood at -$706000.0 (down 1338.6% YoY), while the FY2025 annual figure was $200000.0, up 154.64% from the prior year.
- Receivables slipped to -$706000.0 in Q4 2025 per INBX's latest filing, from $727000.0 in the prior quarter.
- Across five years, Receivables topped out at $1.4 million in Q4 2023 and bottomed at -$706000.0 in Q4 2025.
- Historically, Receivables has averaged $492857.1 across 3 years, with a median of $727000.0 in 2025.
- On a YoY basis, Receivables climbed as much as 857.29% in 2025 and fell as far as 1338.6% in 2025.
- Inhibrx Biosciences' Receivables stood at $1.4 million in 2023, then tumbled by 95.88% to $57000.0 in 2024, then slumped by 1338.6% to -$706000.0 in 2025.
- Business Quant data shows INBX's Receivables at -$706000.0 in Q4 2025, $727000.0 in Q3 2025, and $967000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -506,000.00 |
| Sep 30, 2025 | 837,000.00 |
| Jun 30, 2025 | 967,000.00 |
| Mar 31, 2025 | 214,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | -96,000.00 |
| Jun 30, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.39 Mn |